Brief: Biostax Corp. And Statera Biopharma Inc Reach Mutually Beneficial Dispute Settlement And Amended License Agreement Providing Clearer Clinical And Commercial Pathways For Both Companies
20/04/2023 14:07
April 20 (Reuters) - Immune Therapeutics Inc IMUN.PK :
* BIOSTAX CORP. AND STATERA BIOPHARMA, INC. REACH MUTUALLY
BENEFICIAL DISPUTE SETTLEMENT AND AMENDED LICENSE AGREEMENT
PROVIDING CLEARER CLINICAL AND COMMERCIAL PATHWAYS FOR BOTH
COMPANIES
Source text for Eikon: ID:nGNX65F1nH
Further company coverage: IMUN.PK
Recent news on Biostax
See all newsBrief: Biostax Corp Announces Voluntary Delisting From Otc Pink Market And SEC Deregistration
Brief: Biostax Corp. And Statera Biopharma Inc Reach Mutually Beneficial Dispute Settlement And Amended License Agreement Providing Clearer Clinical And Commercial Pathways For Both Companies
Brief: Immune Therapeutics Inc Announces Management Change
Brief: Statera Biopharma And Immune Therapeutics Inc. Announce Strategic Agreement For Rights To Low Dose Naltrexone
Brief: Immune Therapeutics Today Announces Appointment Of Michael Handley As Its New Chief Executive Officer And Member Of The Board Of Directors